Drug Profile
Research programme: lung disorder biotherapeutics - Vectura/Comprehensive Pneumology Center
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Activaero GmbH; Comprehensive Pneumology Center
- Developer Comprehensive Pneumology Center; Vectura
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lung disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-disorders in Germany (Inhalation)
- 13 Mar 2014 Activaero GmbH has been acquired by Vectura
- 18 Jun 2013 Preclinical trials in Lung disorders in Germany (Inhalation)